Institute of Biochemistry and Signal Transduction, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Int J Mol Sci. 2023 Jan 31;24(3):2652. doi: 10.3390/ijms24032652.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in the world. Metabolic reprogramming is considered a new hallmark of cancer, but it remains unclearly described in HCC. The dysregulation of the PI3K/AKT/mTOR signaling pathway is common in HCC and is, therefore, a topic of further research and the concern of developing a novel target for liver cancer therapy. In this review, we illustrate mechanisms by which this signaling network is accountable for regulating HCC cellular metabolism, including glucose metabolism, lipid metabolism, amino acid metabolism, pyrimidine metabolism, and oxidative metabolism, and summarize the ongoing clinical trials based on the inhibition of the PI3K/AKT/mTOR pathway in HCC.
肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一。代谢重编程被认为是癌症的一个新标志,但在 HCC 中仍描述不清。PI3K/AKT/mTOR 信号通路的失调在 HCC 中很常见,因此是进一步研究的主题,并引起了人们对开发肝癌治疗新靶点的关注。在这篇综述中,我们说明了该信号网络调节 HCC 细胞代谢的机制,包括葡萄糖代谢、脂质代谢、氨基酸代谢、嘧啶代谢和氧化代谢,并总结了基于 PI3K/AKT/mTOR 通路抑制在 HCC 中的临床研究进展。